199 related articles for article (PubMed ID: 22555040)
21. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
22. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
23. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.
Singh S; Singh R; Singh UP; Rai SN; Novakovic KR; Chung LW; Didier PJ; Grizzle WE; Lillard JW
Int J Cancer; 2009 Nov; 125(10):2288-95. PubMed ID: 19610059
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
25. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines.
Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G
Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of matrix metalloproteinase (TIMP)-2 during bovine placentation and at term with or without placental retention.
Dilly M; Hambruch N; Shenavai S; Schuler G; Froehlich R; Haeger JD; Ozalp GR; Pfarrer C
Theriogenology; 2011 Apr; 75(6):1104-14. PubMed ID: 21247626
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
[TBL] [Abstract][Full Text] [Related]
28. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
Avgeris M; Stravodimos K; Scorilas A
Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
[TBL] [Abstract][Full Text] [Related]
29. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.
Cardillo MR; Di Silverio F; Gentile V
Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495
[TBL] [Abstract][Full Text] [Related]
30. The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells.
Wang C; Chen Z; Li Z; Cen J
Leuk Res; 2010 Aug; 34(8):1083-90. PubMed ID: 20138666
[TBL] [Abstract][Full Text] [Related]
31. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate.
Hashimoto K; Kihira Y; Matuo Y; Usui T
J Urol; 1998 Nov; 160(5):1872-6. PubMed ID: 9783977
[TBL] [Abstract][Full Text] [Related]
32. miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.
Ivanovic RF; Viana NI; Morais DR; Moura C; Silva IA; Leite KR; Pontes-Junior J; Nahas WC; Srougi M; Reis ST
BMC Cancer; 2018 Oct; 18(1):992. PubMed ID: 30340564
[TBL] [Abstract][Full Text] [Related]
33. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.
Bi XC; Liu JM; Zheng XG; Xian ZY; Feng ZW; Lou YX; Zhong WD; Wu CL
Clin Invest Med; 2011 Dec; 34(6):E358. PubMed ID: 22129926
[TBL] [Abstract][Full Text] [Related]
34. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
Kalantari E; Abolhasani M; Roudi R; Farajollahi MM; Farhad S; Madjd Z; Askarian-Amiri S; Mohsenzadegan M
Int J Exp Pathol; 2019 Apr; 100(2):123-132. PubMed ID: 31090157
[TBL] [Abstract][Full Text] [Related]
35. Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options.
Janiczek M; Szylberg Ł; Antosik P; Kasperska A; Marszałek A
J Immunol Res; 2020; 2020():4910595. PubMed ID: 32537467
[TBL] [Abstract][Full Text] [Related]
36. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
37. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
38. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
39. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
[TBL] [Abstract][Full Text] [Related]
40. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]